GAINESVILLE, Fla. & SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company focused on developing transformative therapies for rare and neurological diseases with limited treatment options, and Applied Molecular Transport Inc. (Nasdaq: AMTI) (“AMT”), a biopharmaceutical company, announced today that…Read More
Cyclo Therapeutics Inc and Applied Molecular Transport Inc Enter into a Definitive Merger Agreement
